JP2021512121A - プリナブリンおよびｇ−ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 - Google Patents

プリナブリンおよびｇ−ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 Download PDF

Info

Publication number
JP2021512121A
JP2021512121A JP2020541924A JP2020541924A JP2021512121A JP 2021512121 A JP2021512121 A JP 2021512121A JP 2020541924 A JP2020541924 A JP 2020541924A JP 2020541924 A JP2020541924 A JP 2020541924A JP 2021512121 A JP2021512121 A JP 2021512121A
Authority
JP
Japan
Prior art keywords
hours
csf
minutes
prinabrin
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020541924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512121A5 (https=
JPWO2019152530A5 (https=
Inventor
モハンラル，ラモーン
ファン，ラン
ロイド，ジョージ，ケネス
Original Assignee
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド, ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド filed Critical ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド
Publication of JP2021512121A publication Critical patent/JP2021512121A/ja
Publication of JP2021512121A5 publication Critical patent/JP2021512121A5/ja
Publication of JPWO2019152530A5 publication Critical patent/JPWO2019152530A5/ja
Priority to JP2023202765A priority Critical patent/JP2024015120A/ja
Priority to JP2025234643A priority patent/JP2026026377A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
JP2020541924A 2018-02-01 2019-01-30 プリナブリンおよびｇ−ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 Pending JP2021512121A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023202765A JP2024015120A (ja) 2018-02-01 2023-11-30 プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法
JP2025234643A JP2026026377A (ja) 2018-02-01 2025-12-05 プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862625290P 2018-02-01 2018-02-01
US62/625,290 2018-02-01
US201862713486P 2018-08-01 2018-08-01
US62/713,486 2018-08-01
US201862749060P 2018-10-22 2018-10-22
US62/749,060 2018-10-22
US201862757648P 2018-11-08 2018-11-08
US62/757,648 2018-11-08
PCT/US2019/015867 WO2019152530A1 (en) 2018-02-01 2019-01-30 Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023202765A Division JP2024015120A (ja) 2018-02-01 2023-11-30 プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2021512121A true JP2021512121A (ja) 2021-05-13
JP2021512121A5 JP2021512121A5 (https=) 2022-02-08
JPWO2019152530A5 JPWO2019152530A5 (https=) 2022-02-08

Family

ID=67479904

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020541924A Pending JP2021512121A (ja) 2018-02-01 2019-01-30 プリナブリンおよびｇ−ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法
JP2023202765A Pending JP2024015120A (ja) 2018-02-01 2023-11-30 プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法
JP2025234643A Pending JP2026026377A (ja) 2018-02-01 2025-12-05 プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023202765A Pending JP2024015120A (ja) 2018-02-01 2023-11-30 プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法
JP2025234643A Pending JP2026026377A (ja) 2018-02-01 2025-12-05 プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法

Country Status (11)

Country Link
US (1) US20210030843A1 (https=)
EP (1) EP3746076A4 (https=)
JP (3) JP2021512121A (https=)
KR (2) KR20200116477A (https=)
CN (1) CN112105363A (https=)
AU (1) AU2019216305B2 (https=)
BR (1) BR112020015758A2 (https=)
CA (1) CA3089391A1 (https=)
IL (1) IL276197A (https=)
SG (1) SG11202006990TA (https=)
WO (1) WO2019152530A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383691B (es) 2015-03-06 2025-03-14 Beyondspring Pharmaceuticals Inc Método de tratamiento de cáncer asociado con una mutación de ras.
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
WO2017139231A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
RU2760348C2 (ru) 2016-06-06 2021-11-24 Бейондспринг Фармасьютикалс, Инк. Способ уменьшения нейтропении
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
US11267858B2 (en) 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
US11684655B2 (en) 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
EP4045046A4 (en) * 2019-10-15 2024-01-10 Beyondspring Pharmaceuticals Inc. Methods and compositions for treating iron disorders
JP2023505506A (ja) * 2019-12-05 2023-02-09 ハンミ ファーマシューティカルズ カンパニー リミテッド 化学療法または放射線療法で誘導された好中球減少症を治療する方法
CA3186416A1 (en) * 2020-07-17 2022-01-20 John A. Barrett Methods of treating chemotherapy induced neutropenia using fixed doses of g-csf protein complex
WO2022133492A1 (en) * 2020-12-18 2022-06-23 Beyondspring Pharmaceuticals, Inc. Compositions and methods for generating anti-tumor immune response
KR102375269B1 (ko) * 2021-01-27 2022-03-17 한미약품 주식회사 단백질 액상 제제 및 이의 제조방법
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
FI131561B1 (en) * 2023-12-28 2025-06-30 Faron Pharmaceuticals Oy CLEVER-1 INHIBITOR TO PROMOTE HEMATOLOGICAL RECOVERY WHEN USING CHEMOTHERAPY
CN120682197A (zh) * 2024-03-19 2025-09-23 大连万春布林医药有限公司 普那布林的盐晶型
CN119371407A (zh) * 2024-06-27 2025-01-28 青岛海合生物科技有限公司 一种具有抗肿瘤功效的2,5-二酮哌嗪类化合物及其在制备治疗和/或预防中性粒细胞减少症的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016536352A (ja) * 2013-10-11 2016-11-24 ビヨンドスプリング インコーポレイテッド プリナブリン及びタキサンの組合せがん治療
WO2017214052A1 (en) * 2016-06-06 2017-12-14 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
JP2020514412A (ja) * 2017-02-01 2020-05-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症の低減方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110132327A (ko) * 2009-01-16 2011-12-07 테바 파마슈티컬 인더스트리즈 리미티드 재조합 인간 알부민-인간 과립구 콜로니 자극 인자 융합 단백질의 신규 안정한 제형

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016536352A (ja) * 2013-10-11 2016-11-24 ビヨンドスプリング インコーポレイテッド プリナブリン及びタキサンの組合せがん治療
WO2017214052A1 (en) * 2016-06-06 2017-12-14 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
JP2022058964A (ja) * 2016-06-06 2022-04-12 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
JP2020514412A (ja) * 2017-02-01 2020-05-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症の低減方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"History of Changes for Study: NCT03294577, Plinabulin vs. Pegfilgrastim in Reducing the Duration of", CLINICALTRIALS.GOV ARCHIVE [ONLINE], JPN6023030912, 16 January 2018 (2018-01-16), ISSN: 0005118955 *
BLOOD, vol. 128, no. 22, JPN6022050095, 2016, pages 2508, ISSN: 0004932036 *

Also Published As

Publication number Publication date
US20210030843A1 (en) 2021-02-04
IL276197A (en) 2020-09-30
CA3089391A1 (en) 2019-08-08
SG11202006990TA (en) 2020-08-28
KR20260023097A (ko) 2026-02-20
EP3746076A1 (en) 2020-12-09
WO2019152530A1 (en) 2019-08-08
JP2026026377A (ja) 2026-02-16
JP2024015120A (ja) 2024-02-01
RU2020126600A (ru) 2022-03-01
KR20200116477A (ko) 2020-10-12
EP3746076A4 (en) 2021-12-22
NZ766454A (en) 2024-02-23
AU2019216305B2 (en) 2024-11-21
BR112020015758A2 (pt) 2020-12-08
AU2019216305A1 (en) 2020-08-27
CN112105363A (zh) 2020-12-18

Similar Documents

Publication Publication Date Title
JP2021512121A (ja) プリナブリンおよびｇ−ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法
US12458638B2 (en) Method of stimulating neutrophil survival and reducing neutropenia
JP7405881B2 (ja) 好中球減少症を低減させるための組成物および方法
JP7350015B2 (ja) プリナブリンの投与による血小板減少症を軽減するための組成物および方法
RU2798103C2 (ru) Композиция и способ уменьшения вызванной химиотерапией нейтропении с помощью введения плинабулина и агента г-ксф
RU2790989C2 (ru) Способ уменьшения нейтропении
RU2790989C9 (ru) Способ уменьшения нейтропении
NZ755858B2 (en) Method of reducing neutropenia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220131

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231130